Literature DB >> 16205313

Genetic polymorphisms and sepsis.

John Arcaroli1, Michael B Fessler, Edward Abraham.   

Abstract

Sepsis is a polygenic and complex syndrome that is initiated by infection and is characterized by a systemic inflammatory response. Genetic polymorphisms in the immune response to infection have been shown to be associated with clinical outcomes. Functional and association studies involving genetic polymorphisms in essential genes, including Toll-like receptors, cytokines, and coagulation factors, have provided important insights into the mechanisms involved in the pathogenesis of sepsis-induced organ dysfunction. The advancement of high-throughput single nucleotide polymorphism (SNP) genotyping will provide valuable information on the interaction of multiple allelic variants and clinical outcome. More precise categorization of patients based on genetic background is likely to lead to individualized targeted treatment. Future therapeutic trials as well as actual treatment regimens for patients with sepsis are likely to be designed to target specific genotypes and associated cellular responses, maximizing clinical response and patient safety.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205313     DOI: 10.1097/01.shk.0000180621.52058.e1

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  53 in total

1.  IL-10 polymorphism associated with decreased risk for mortality after burn injury.

Authors:  Ryan M Huebinger; Fernando Rivera-Chavez; Ling-Yu Chang; Ming-Mei Liu; Joseph P Minei; Gary F Purdue; John L Hunt; Brett D Arnoldo; Robert C Barber
Journal:  J Surg Res       Date:  2010-08-06       Impact factor: 2.192

2.  Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.

Authors:  James W Dear; Pajaree Lilitkarntakul; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

Review 3.  A generic research paradigm for identification and validation of early molecular diagnostics and new therapeutics in common disorders.

Authors:  Keith D Coon; Travis L Dunckley; Dietrich A Stephan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 4.  Recent advances in genetic predisposition to clinical acute lung injury.

Authors:  Li Gao; Kathleen C Barnes
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-02-13       Impact factor: 5.464

Review 5.  Mechanisms and regulation of the gene-expression response to sepsis.

Authors:  Timothy T Cornell; James Wynn; Thomas P Shanley; Derek S Wheeler; Hector R Wong
Journal:  Pediatrics       Date:  2010-05-17       Impact factor: 7.124

6.  Tumor necrosis factor -308 polymorphism (rs1800629) is associated with mortality and ventilator duration in 1057 Caucasian patients.

Authors:  Eizo Watanabe; Barbara A Zehnbauer; Shigeto Oda; Yasunori Sato; Hiroyuki Hirasawa; Timothy G Buchman
Journal:  Cytokine       Date:  2012-06-28       Impact factor: 3.861

7.  Association between urokinase haplotypes and outcome from infection-associated acute lung injury.

Authors:  John Arcaroli; Jeff Sankoff; Nianjun Liu; David B Allison; James Maloney; Edward Abraham
Journal:  Intensive Care Med       Date:  2007-11-10       Impact factor: 17.440

8.  Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis.

Authors:  Rajesh K Thimmulappa; Hannah Lee; Tirumalai Rangasamy; Sekhar P Reddy; Masayuki Yamamoto; Thomas W Kensler; Shyam Biswal
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

Review 9.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

Authors:  Derek S Wheeler; Basilia Zingarelli; William J Wheeler; Hector R Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2009-06

10.  Comparative genomics RNAi screen identifies Eftud2 as a novel regulator of innate immunity.

Authors:  Lesly De Arras; Rebecca Laws; Sonia M Leach; Kyle Pontis; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  Genetics       Date:  2013-12-20       Impact factor: 4.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.